The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies

  1. Alexandra J Spencer
  2. Susan Morris
  3. Marta Ulaszewska
  4. Claire Powers
  5. Reshma Kailath
  6. Cameron Bissett
  7. Adam Truby
  8. Nazia Thakur
  9. Joseph Newman
  10. Elizabeth R Allen
  11. Indra Rudiansyah
  12. Chang Liu
  13. Wanwisa Dejnirattisai
  14. Juthathip Mongkolsapaya
  15. Hannah Davies
  16. Francesca R Donnellan
  17. David Pulido
  18. Thomas P. Peacock
  19. Wendy S. Barclay
  20. Helen Bright
  21. Kuishu Ren
  22. Gavin Screaton
  23. Patrick McTamney
  24. Dalan Bailey
  25. Sarah C Gilbert
  26. Teresa Lambe
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins. In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine (AZD2816) which expresses the spike protein of the Beta VoC (B.1.351). We demonstrate that AZD2816 is immunogenic after a single dose. When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ [AZD1222]), high titre binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) are induced. In addition, a strong and polyfunctional T cell response was measured in these booster regimens. These data support the ongoing clinical development and testing of this new variant vaccine.

Related articles

Related articles are currently not available for this article.